Research programme: vaccines - Dyadic International/EnGen Bio

Drug Profile

Research programme: vaccines - Dyadic International/EnGen Bio

Latest Information Update: 21 Sep 2016

Price : $50

At a glance

  • Originator Dyadic International; EnGen Bio
  • Class Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Unspecified

Most Recent Events

  • 08 Aug 2016 Discontinued for Undefined indication in Netherlands (Parenteral)
  • 12 May 2016 Development is ongoing in Netherlands
  • 02 May 2011 Early research in Undefined indication in Netherlands (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top